한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제30권2호
  • /
  • Pages.102-112
  • /
  • 2020
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지
DOI QR코드

DOI QR Code

건강보험 청구자료를 이용한 궤양성 대장염 치료제의 처방 양상과 전신 스테로이드 처방에 미치는 영향요인

Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database

  • 김지율 (성균관대학교 약학대학) ;
  • 박소희 (성균관대학교 약학대학) ;
  • 신주영 (성균관대학교 약학대학)
  • 투고 : 2020.03.18
  • 심사 : 2020.05.29
  • 발행 : 2020.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To analyze the prescription patterns for the treatment of ulcerative colitis (UC) and to investigate factors co-occurring with systemic corticosteroid use. Methods: We used patient-level data from Korean National Health Insurance claims database to identify patients diagnosed with UC (ICD-10 code : K51) and their medications prescribed for UC between January 1 and Decemeber 31, 2017. We found that medications for UC treatment were 5-aminosalicylic acid (5-ASA), immunomodulators, biologics, and corticosteroids. We presented the prescription pattern according to the sex, age group, type of health insurance, site of UC, type of medical institution, and concomitant medication. To evaluate factors associated with prescription of systemic corticosteroids for UC, we used a multivariate logistic regression model to estimate adjusted odds ratios (aORs) and their 95% confidence intervals (CIs). Results: Of 1,469 UC patients, 74.5% used 5-ASA and 15.2% used systemic corticosteroids. 5-ASA constituted 77.5% of all prescriptions and systemic corticosteroids accounted for 13.1%. The most widely used therapy was 5-ASA monotherapy (54.8%), followed by a double therapy with 5-ASA and immunomodulators (8.2%) or 5-ASA and systemic corticosteroids (7.2%). Systemic corticosteroids were more likely to be prescribed with immunomodulators (aOR=1.88, 95% CI=1.54-2.28) and biologics (aOR=2.82, 95% CI=2.28-3.50) than without them. Conclusions: We found that 15.2% of UC patients were prescribed with a systemic corticosteroid, which is less than reported previously. Systemic corticosteroids were more likely to be prescribed with immunomodulators and biologics.

키워드

참고문헌

  1. Yang DH, Yang SK. Trends in the incidence of ulcerative colitis in Korea. Korean J Med 2009;76(6):637-42.
  2. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease. New Engl J Med 1994;331(13):836-41. https://doi.org/10.1056/NEJM199409293311303
  3. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn’s disease. Inflamm Bowel Dis 2008;15(3):375-82. https://doi.org/10.1002/ibd.20777
  4. Reinisch W, Sandborn WJ, Bala M, et al. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007;13(9):1135-40. https://doi.org/10.1002/ibd.20165
  5. Bernklev T, Jahnsen J, Schulz T, et al. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol 2005;17(10):1037-45. https://doi.org/10.1097/00042737-200510000-00006
  6. Na SY, Moon W. Evolving therapeutic strategies in the inflammatory bowel disease. Korean J Gastroenterol 2018;71(2):61-8. https://doi.org/10.4166/kjg.2018.71.2.61
  7. Jang BI. Changing paradigm in the management of inflammatory bowel disease. Korean J Gastroenterol 2015;65(5):268-72. https://doi.org/10.4166/kjg.2015.65.5.268
  8. Kim YM, Park SH, Yang SK, et al. Clinical characteristics and longterm course of ulcerative colitis in Korea. Intest Res 2006;4(1):12-21.
  9. Ha JE, Jang EJ, Im SG, Sohn HS. Medication use and drug expenditure in inflammatory bowel disease: based on korean national health insurance claims data (2010-2014). Korean J Clin Pharm 2019;29(2):79-88.
  10. Kim DS, Lee HJ, Son IJ, Kim GS, Shin JY, Lee KS. Retrospective drugs utilization review study for chronic kidney disease using national health insurance database. Yakhak Hoeji 2009;53(3):138-44.
  11. Choi CH, Moon W, Kim YS, et al. Second Korean guideline for the management of ulcerative colitis. Korean J Gastroenterol 2017;69(1):1-28. https://doi.org/10.4166/kjg.2017.69.1.1
  12. Jeen YT, Kim J. Advances in ulcerative colitis therapy. Korean J Med 2009;76(6):654-60.
  13. Health Insurance Review & Assessment Service Healthcare Bigdata Hub. Disease Subclassification Statistics (K51). Available from opendata.hira.or.kr/op/opc/olap3thDsInfo.do. Accessed December 27, 2019.
  14. Korean Statistical Information Service. Total Population and Population Growth Rate. Available from kosis.kr/statisticsList/ statisticsListIndex.do?menuId=M_01_01&vwcd=MT_ZTITLE&p armTabId=M_01_01&statId=1962001&themaId=A#SelectStatsBo xDiv. Accessed December 27, 2019.
  15. Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. Inflamm Bowel Dis 2015;21(3):623-30. https://doi.org/10.1097/MIB.0000000000000313
  16. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14(2):111-9. https://doi.org/10.5217/ir.2016.14.2.111
  17. Chang D, Lee K, Kim J, et al. Follow-up of ulcerative colitis: Shortterm outcome to medical treatment and relapse rates. Korean J Gastroenterol 1994;26:907-18.
  18. Lee JW, Im JP, Cheon JH, Kim YS, Kim JS, Han DS. Inflammatory bowel disease cohort studies in Korea: present and future. Intest Res 2015;13(3):213. https://doi.org/10.5217/ir.2015.13.3.213
  19. Chae HB, Jung YS, Park DI, et al. Differences in the prognosis according to the periods of diagnosis in ulcerative colitis. Korean J Gastroenterol 2014;64(2):93-7. https://doi.org/10.4166/kjg.2014.64.2.93
  20. Kim CG, Kim JW, Kim HD, et al. Clinical features of Crohn's disease in Korea. Korean J Gastroenterol 2002;40(3):173-80.
  21. Ye BD, Jang BI, Jeen YT, Lee KM, Kim JS, Yang SK. Diagnostic guideline of Crohn’s disease. Korean J Gastroenterol 2009; 53(3):161-76.
  22. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006;24(2):319-30. https://doi.org/10.1111/j.1365-2036.2006.02974.x
  23. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. BMJ 1955;2:1041-8.
  24. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX$^{(R)}$ extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143(5):1218-26.e2. https://doi.org/10.1053/j.gastro.2012.08.003
  25. Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63(3):433-41. https://doi.org/10.1136/gutjnl-2012-304258
  26. Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left?sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17(12):1471-80. https://doi.org/10.1046/j.1365-2036.2003.01609.x
  27. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60(5):571-607. https://doi.org/10.1136/gut.2010.224154